PriceTargets.com logo

Medicis Pharmaceutical - MRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 3.41%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$26.11 As of 10/29/2024 01:00 AM ET
▲ +0.53 (2.07%)
Get New Medicis Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRX

Analyst Price Target is $27.00
▲ +3.41% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Medicis Pharmaceutical in the last 3 months. The average price target is $27.00, with a high forecast of $33.00 and a low forecast of $24.00. The average price target represents a 3.41% upside from the last price of $26.11.

This chart shows the closing price for MRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Medicis Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/7/2024BarclaysBoost TargetOverweight ➝ Overweight$28.00 ➝ $30.00
8/15/2024BarclaysBoost TargetOverweight ➝ Overweight$25.00 ➝ $28.00
8/14/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$27.00 ➝ $27.00
5/20/2024The Goldman Sachs GroupInitiated CoverageBuy$33.00
5/20/2024BarclaysInitiated CoverageOverweight$25.00
5/20/2024Piper SandlerInitiated CoverageOverweight$27.00
5/20/2024UBS GroupInitiated CoverageBuy$27.00
5/20/2024Jefferies Financial GroupInitiated CoverageBuy$24.00
5/20/2024Keefe, Bruyette & WoodsInitiated CoverageOutperform$24.00
5/20/2024CitigroupInitiated CoverageBuy$24.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Medicis Pharmaceutical logo
Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).
Read More

Today's Range

Now: $26.11
Low: $25.42
High: $26.42

50 Day Range

MA: N/A

52 Week Range

Now: $26.11

Volume

870,715 shs

Average Volume

494,775 shs

Market Capitalization

$1.84 billion

P/E Ratio

N/A

Dividend Yield

2.20%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicis Pharmaceutical?

The following Wall Street research analysts have issued stock ratings on Medicis Pharmaceutical in the last twelve months: Barclays PLC, Citigroup Inc., Jefferies Financial Group Inc., Keefe, Bruyette & Woods, Piper Sandler, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for MRX.

What is the current price target for Medicis Pharmaceutical?

7 Wall Street analysts have set twelve-month price targets for Medicis Pharmaceutical in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 3.4%. The Goldman Sachs Group, Inc. has the highest price target set, predicting MRX will reach $33.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $24.00 for Medicis Pharmaceutical in the next year.
View the latest price targets for MRX.

What is the current consensus analyst rating for Medicis Pharmaceutical?

Medicis Pharmaceutical currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRX will outperform the market and that investors should add to their positions of Medicis Pharmaceutical.
View the latest ratings for MRX.

What other companies compete with Medicis Pharmaceutical?

Other companies that are similar to Medicis Pharmaceutical include BGC Group, StoneX Group, Forge Global, TOP Financial Group and Garden Stage. Learn More about companies similar to Medicis Pharmaceutical.

How do I contact Medicis Pharmaceutical's investor relations team?

Medicis Pharmaceutical's physical mailing address is 8125 N Hayden Rd, SCOTTSDALE, AZ 85258-2463, United States. The healthcare company's listed phone number is +1-212-5992000 and its investor relations email address is [email protected]. The official website for Medicis Pharmaceutical is www.Medicis.com. Learn More about contacing Medicis Pharmaceutical investor relations.